To strengthen its hereditary angioedema (HAE) portfolio, BioCryst has agreed to acquire Astria Therapeutics in a deal valued at up to US$700 M. Through this acquisition, BioCryst will gain access to Astria’s lead candidate, navenibart (STAR-0215), currently in Phase III trials for HAE, as well as STAR-0310, which is undergoing a Phase Ia trial for atopic dermatitis (AD). This move expands BioCryst’s HAE existing pipeline beyond its own marketed oral drug, Orladeyo (berotralstat), which was approved in the US in 2020 for the prevention of HAE attacks.